iQur is at the forefront of vaccine research and development, tackling major global health challenges and emerging infections.
Our vaccines are based on a scaffold formed from hepatitis B core protein that presents antigens of interest derived from the target pathogen. This virus- like-particle platform is safe and can be used repeatedly.
Our lead candidate is a universal influenza vaccine, FLUTCORE, that is effective in animal models. We now seek funding to run a clinical trial of safety and effectiveness.
Founded at the University of Southampton, now linked to University College London, iQur is a London-based biotech with a great future.